The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging checks, laboratory tests and pathological activation.
The platform can assist in matching domestic and foreign authoritative experts and teams to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that have previously been difficult to treat have been significantly improved. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of lupus type I. The platform serves the China International Medical Service System, a team of nationally authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: Remote pre-diagnosis: by the team of experts to review the history, clarify the direction of diagnosis and medical advice on: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.